Eli Lilly 2011 Annual Report Download - page 16

Download and view the complete annual report

Please find page 16 of the 2011 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 164

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164

FORM 10-K
Part I
Item 1. Business
Eli Lilly and Company (the “company” or “registrant”) was incorporated in 1901 in Indiana to succeed to the drug
manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover, develop,
manufacture, and sell products in one significant business segment—pharmaceutical products. We also have an
animal health business segment, whose operations are not material to our financial statements.
Our mission is to make medicines that help people live longer, healthier, more active lives. Our strategy is to create
value for all our stakeholders by accelerating the flow of innovative new medicines that provide improved outcomes
for individual patients. Most of the products we sell today were discovered or developed by our own scientists, and
our success depends to a great extent on our ability to continue to discover, develop, and bring to market innovative
new medicines.
We manufacture and distribute our products through facilities in the United States, Puerto Rico, and 15 other
countries. Our products are sold in approximately 130 countries.
Products
Our products include:
Neuroscience products, our largest-selling product group, including:
•Zyprexa®,for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder,
and bipolar maintenance
•Zyprexa Relprevv™ (Zypadhera®in the European Union), a long-acting intramuscular injection formulation of
Zyprexa
•Cymbalta®, for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized
anxiety disorder, and in the U.S. for the management of fibromyalgia and of chronic musculoskeletal pain due to
chronic low back pain or chronic pain due to osteoarthritis
•Strattera®,for the treatment of attention-deficit hyperactivity disorder in children, adolescents, and in the U.S.
in adults
•Prozac®,for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and
panic disorder
•Symbyax®,for the treatment of bipolar depression and treatment-resistant depression.
Endocrinology products, including:
•Humalog®,Humalog Mix 75/25™, and Humalog Mix 50/50™, for the treatment of diabetes
•Humulin®,for the treatment of diabetes
•Byetta®, for the treatment of type 2 diabetes
•Bydureon®,approved in Europe in 2011 and in the U.S. in January 2012 for the treatment of type 2 diabetes (see
“Pharmaceutical Marketing Collaborations” below for information about the termination of our collaboration
with Amylin Pharmaceuticals for Byetta and Bydureon)
•Actos®,for the treatment of type 2 diabetes (marketed by us only in certain countries outside the U.S.)
•Tradjenta™, approved and launched in 2011 for the treatment of type 2 diabetes
•Evista®,for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the
risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high
risk for invasive breast cancer
•Forteo®,for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture and for
glucocorticoid-induced osteoporosis in men and postmenopausal women
•Humatrope®,for the treatment of human growth hormone deficiency and certain pediatric growth conditions
•Axiron®, a topical solution of testosterone, applied by underarm applicator, for replacement therapy in men for
certain conditions associated with a deficiency or absence of testosterone (launched in 2011).
Oncology products, including:
•Alimta®,for the first-line treatment, in combination with another agent, of non-small cell lung cancer for
patients with non-squamous cell histology; for the second-line treatment of non-small cell lung cancer; in the
European Union as monotherapy for the maintenance treatment of locally advanced or metastatic non-small
cell lung cancer in patients with non-squamous cell histology whose disease has not progressed immediately
following platinum-based chemotherapy; and in combination with another agent, for the treatment of malignant
pleural mesothelioma
2